

**5<sup>th</sup> March 2026**

**The ISH Venues, 1 Park Crescent, Regents Park, London.**

---

## **Programme**

### **Implementing the Latest HBV & HDV Guidelines into Clinical Care**

09:15 – 09:45	Arrival - Registration and coffee
09:45 – 09:50	Introduction <ul style="list-style-type: none"><li>- <i>Prof Patrick Kennedy, (QMUL)</i></li></ul>
<b>09:45 - 11.10</b>	<b>Session 1 – Clinical Decision Making in HBV: Evidence, Uncertainty &amp; Consensus</b> <b>(Chairs: Dr Kosh Agarwal &amp; Prof Philippa Matthews - TBC)</b>
09:45 – 10:05	Challenges of the EASL HBV CPG 2025 in clinical practice <ul style="list-style-type: none"><li>- <i>Prof Markus Cornberg, (Hannover Medical School, Germany)</i></li></ul>
10:05 – 10:25	Treated vs Untreated patients: are we doing the right thing based on recent guidelines? <ul style="list-style-type: none"><li>- <i>Prof Maud Lemoine, (Imperial College, London)</i></li></ul>
10:25 – 10:45	London HBV consensus recommendations <ul style="list-style-type: none"><li>- <i>Prof Daniel Forton, (City St George's, University of London) - TBC</i></li></ul>
10:45 – 11:05	Panel Discussion & questions
<b>11.05– 11.25</b>	<b>Coffee and Exhibition</b>
<b>11.25 – 12:45</b>	<b>Session 2 – From Risk Stratification to Cure-Readiness in CHB</b> <b>(Chairs: Prof Geoff Dusheiko &amp; Dr Bo Wang - TBC)</b>
11:25 – 11:45	Rethinking Risk in CHB: From ALT Thresholds to Metabolic Comorbidity <ul style="list-style-type: none"><li>- <i>Dr Upkar Gill (QMUL)</i></li></ul>
11:45 – 12:05	Are we using nucleos(t)ide analogues optimally – cost effectiveness analysis <ul style="list-style-type: none"><li>- <i>Dr Ricky Sinharay (Royal Berkshire NHS Foundation Trust) - TBC</i></li></ul>
12:05 – 12:25	Functional cure in CHB: what UK clinicians need to understand now <ul style="list-style-type: none"><li>- <i>Prof Stuart McPherson (Newcastle University) - TBC</i></li></ul>
12:25 – 12:45	Panel Discussion & questions
<b>12:45 – 14:00</b>	<b>Lunch and Exhibition</b>

**14:00 - 15:20      Session 3 – Hepatitis Delta in Practice: From Detection to Treatment  
(Chairs: Dr Upkar Gill & Dr Shevanthi Nayagam)**

14:00 – 14:20	Prevalence of Hepatitis Delta & disease burden in the UK - Dr Ruth Simmons (UKHSA)
14:20 – 14:40	HDV diagnostics in practice: antibody, RNA, reflex testing & laboratory pathways - Dr Ivana Carey (Kings College London) - TBC
14:40 – 15:00	Bulevirtide in practice: patient selection, monitoring and service delivery - Dr Doug MacDonald & AHP (Royal Free Hospital) - TBC
15:00 – 15.20	Panel Discussion & questions

**15.20 – 15:40      Coffee and Exhibition**

**15:40 – 16:50      Session 4 – Viral Hepatitis Care in the NHS: Access, Engagement & Experience (Chairs: Dr Stuart Flanagan & Dr Monica Desai)**

15:40 – 16:00	Patient perspectives
16:00 – 16.20	Challenges in case finding & engagement in care - UKHSA
16:20 – 16:40	Viral hepatitis in the liver transformation programme - Dr Richard Aspinall (Portsmouth Hospitals University NHS Trust) - TBC
16:40 – 16:50	Closing remarks - Prof. Patrick Kennedy, QMUL

BASL will be approaching pharmaceutical companies to provide funding for this meeting.

They will have had no influence over, or input into the content of the materials used at this meeting including the programme and selection of speakers.

**For queries, please contact [kim@basl.org.uk](mailto:kim@basl.org.uk) Tel. 01543 442154**

CPD will be applied for from the Federation of the Royal Colleges of Physicians of the United Kingdom for this BASL BVHG Educational Meeting.